logo
Plus   Neg
Share
Email

Dillard's Posts Q1 Loss, Re-opens 149 Locations; Shares Up 6%

Dillard's, Inc. (DDS) Thursday reported first quarter loss of $162.0 million or $6.94 per share, compared to net income of $78.6 million or $2.99 per share last year.

Net sales for the quarter was $786.7 million, down from $1.47 billion last year.

Analysts polled by Thomson Reuters estimated earnings of $0.08 per share and revenues of $1.09 billion.

Dillard's said it has re-opened149 locations to date, including 24 clearance centers. The Company currently plans to re-open 116 Dillard's stores and 5 clearance centers next week.

CEO William Dillard said, "COVID-19 has impacted every aspect of our business. The mall business in general and department stores, specifically, have been particularly hard hit. While our balance sheet was already strong, we took decisive, sometimes difficult, actions to preserve liquidity and ensure our long-term viability. As we re-open stores, we see positive things happening. We believe people are ready to get out and shop. We are hoping this is the start of better times."

DDS closed Thursday's trading at $23.08, down $0.95 or 3.95%, on the NYSE. The stock, however, gained $1.37 or 5.94% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk, chief executive of electric car maker Tesla, said its own battery cells, which are under development now, will not reach high-volume production until 2022. This delay can affect the Cybertruck, Semi, and Roadster programs. He also said the company intends to increase battery cell purchases from partners Panasonic, LG & CATL, and possibly other partners. U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test.
RELATED NEWS
Follow RTT